PipelineReview.com3 小时
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma ...
Humacyte: FDA Waiting Game Bleeding Company Dry
Read about the struggles facing Humacyte's ATEV technology as FDA approval is delayed, raising financial strain and ...
24/7 Wall St18 小时
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT(TM) (cosibelimab-ipdl)
UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...
The FDA Hasn’t Inspected This Drug Factory After 7 Recalls for the Same Flaw, 1 ...
Glenmark Pharmaceuticals issued seven recalls for pills that didn’t dissolve properly, records show. All were made at the ...
ctpublic20 小时
Are you confused by labels that tell you when food is freshest? Here's some guidance
The FDA is trying to find out why food companies use the labels they do. Food waste and food safety experts share what these ...